Finally, “receptor fingerprints” not only differentiated patients with PSP from control subjects neurochemically but also segregated PSP subgroups when clinical parameters such as presence of frontal presentation and severity of tau pathology were taken into consideration. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.